# Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy

> **NCT05995236** · — · UNKNOWN · sponsor: **Methodist Health System** · enrollment: 400 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** PSMA radionuclide therapy

## Key facts

- **NCT ID:** NCT05995236
- **Lead sponsor:** Methodist Health System
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-02
- **Primary completion:** 2024-08-02
- **Final completion:** 2024-08-02
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05995236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05995236, "Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05995236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*